Microencapsulating and Banking Living Cells for Cell-Based Medicine

Wujie Zhang\textsuperscript{1,2} and Xiaoming He\textsuperscript{1,2,3,*}

\textsuperscript{1}Department of Biomedical Engineering,
\textsuperscript{2}Davis Heart and Lung Research Institute, and
\textsuperscript{3}James Comprehensive Cancer Center

The Ohio State University
Columbus, OH 43210

Submitted March 2011. Accepted for publication August 2011.

ABSTRACT

A major challenge to the eventual success of the emerging cell-based medicine such as tissue engineering, regenerative medicine, and cell transplantation is the limited availability of the desired cell sources. This challenge can be addressed by cell microencapsulation to overcome the undesired immune response (i.e., to achieve immunoisolation) so that non-autologous cells can be used to treat human diseases, and by cell/tissue preservation to bank living cells for wide distribution to end users so that they are readily available when needed in the future. This review summarizes the status quo of research in both cell microencapsulation and banking the microencapsulated cells. It is concluded with a brief outlook of future research directions in this important field.

Keywords: microencapsulation, cryopreservation, vitrification, cytotherapy, gene therapy, transplantation

1. INTRODUCTION

A major challenge to the emerging cell-based medicine for the treatment of diseases is the host immune rejection of the transplanted donor cells or engineered tissue [1 - 10]. One way to address this problem is to use drugs to achieve immunosuppression. However, suppressing the patient’s immune system may put the patient at risk for many other diseases. An alternative is to encapsulate living cells in small microcapsules to achieve immunoisolation of the cells (see Figure 1) so that they can survive well in the patient’s body after transplantation [1 - 10]. The microcapsule’s membrane protects the encapsulated cells from being damaged by both the host’s immune system and mechanical stresses while allowing free diffusion of nutrients and metabolic wastes for the cells to survive. Moreover, the membrane could be designed to achieve

*Corresponding author: Xiaoming He, Department of Biomedical Engineering, The Ohio State University, 1080 Carmack Road, Columbus, OH 43210. Phone: (614) 292-6992. Fax: (614) 292-7301. Email: he.429@osu.edu.
controlled/sustained release of therapeutic product produced by the encapsulated cells to treat a variety of diseases including diabetes, liver failure, as well as neurodegenerative, musculoskeletal, and cardiovascular diseases [1 - 10].

In this review, the materials and/or methods used for microencapsulating a variety of cells and banking (by cryopreservation) the microencapsulated cells for future use are summarized. The latter is an enabling technology for the eventual success of cell-based medicine because cell-based commercial products must be banked for wide distribution to end users (e.g., hospitals and medical centers). This review concludes with a brief outlook of future directions in this important field.

Figure 1. A schematic illustration of the concept of immunoisolation by encapsulating living cells in microcapsules that have a semipermeable wall to allow free diffusion of nutrients, metabolic wastes, and therapeutic agents while blocking any host immune mediators from getting in contact with the encapsulated cells.

2. MATERIALS AND METHODS FOR MICROENCAPSULATION OF MAMMALIAN CELLS

2.1. Materials for Cell Microencapsulation
A variety of natural and synthetic polymers (Table 1) have been used for cell microencapsulation, including alginate, poly(ethylene glycol) (PEG), chitosan, collagen, dextran, poly(vinyl alcohol) (PVA), agarose (with or without gelatin), hyaluronic acid (HA), 2-hydroxyethyl methacrylate (HEMA), poly(lactic-co-glycolic acid) (PLGA) [3 - 6, 11 - 13]. In general, natural materials are biodegradable and might have a better biocompatibility, while synthetic materials have more consistent compositions [11]. Among these materials, alginate is most widely used for cell microencapsulation due to its natural origin (e.g., brown seaweeds) and excellent biocompatibility [3 - 5]. Alginites are linear block polymers consisting of $\alpha$-L-
guluronic acid (G block) and β-D-manuronic acid (M block). The gelation of alginate in divalent cations is a result of the formation of the calcium junctions of GG-GG, MG-GG and MG-MG between alginate molecules. The G and M contents vary with alginate sources and can affect the gel properties including the mechanical strength, biocompatibility and permeability [14, 15]. Moreover, other divalent cations, such as Ba\(^{2+}\) and Sr\(^{2+}\), have been used for microencapsulation. The gel properties are shown to be dependent on the cross-linking ion (due to different affinity to alginate) used, ion concentration, and time for gelation [16, 17]. Interestingly, stable, homogeneous alginate microcapsules can be produced by injecting BaCl\(_2\) crystals into the microcapsule core using the crystal gun technique before their contact with external Ba\(^{2+}\). On the contrary, inhomogeneous capsule has been designed by combining high G content alginate with Ca\(^{2+}\) and Ba\(^{2+}\) [17]. This inhomogeneous system is shown to have high stability and allow for long-term in vivo function of human islet graft [18]. Many studies show that purified sodium alginate (after removal of visible aggregates, proteins and endotoxin content) could improve the biocompatibility and mechanical strength of alginate-based microcapsules [3, 5, 15, 19-24]. The impurities in alginate may explain the inconsistency regarding the bio-incompatibility of alginate microcapsules reported in the literature. In short, both the composition and purity determine the biocompatibility of alginate.

To increase their stability and to reduce the wall permeability (for immunoisolation) of the microcapsules, the plain alginate microcapsules are often coated first with a polycation and then another layer of alginate. Various polycations have been used including poly-L-lysine (PLL), poly-L-ornithine (PLO), chitosan, lactose modified chitosan and photopolymerized materials [11]. Among them, PLL is most commonly used to produce the classic alginate-PLL-alginate (APA) microcapsules. PLL binds to the alginate molecules next to the capsule surface by forming complexes with the M-G sequences in alginate, which decreases the porosity of the microcapsule wall. When the two molecules interact strongly, the PLL is converted from β-sheet to α-helix and surrounded by a larger helix of the alginate molecule [3, 6, 15, 20, 25, 26].

Chitosan, one kind of biodegradable polysaccharide with structural characteristics similar to glycosaminoglycans, has attracted much attention as an alternative polycation in preparing microcapsules. Chitosan has excellent cell affinity [27, 28], and can be obtained by the N-deacetylation of chitin, poly[β(1→4)-2-acetamido-2-deoxy-D-glucopyranose]. Chitosan has been used to microencapsulate PC12 cells, R208F cells, Human RBCs, HepG2 cells, BHK-21 cells, chondrocytes, and bone marrow stem cells [19, 29 - 35]. However, the encapsulation process involving high molar mass chitosan (> 100 kDa) must be carried out under pH < 6.0 to ensure chitosan solubility, which is too acidic to most mammalian cells. Moreover, the coating using high molar mass chitosan takes a relatively long time (up to 30 min). This prolonged exposure of mammalian cells to the low pH results in low cell viability after coating. In addition, the swelling and breaking of alginate-chitosan-alginate (ACA) microcapsules are difficult to overcome when liquefying the alginate core using sodium citrate solution [19, 36, 37]. Moreover, long-term biocompatibility of chitosan and other polycations in vivo needs to be further evaluated rigorously. Again, the origin, purity and properties of these materials should be taken into account in assessing their biocompatibility [38].
### Table 1. A summary of commonly used materials for cell microencapsulation and their applications

<table>
<thead>
<tr>
<th>Materials</th>
<th>Cell Type(s)</th>
<th>Targeted Diseases or Applications</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alginate-PLL*</td>
<td>Islets, hepatocytes, HEK 293 cells, mesenchymal stem cells, embryonic stem cells</td>
<td>Diabetes, cancer, liver neurodegenerative, musculoskeletal, and cardiovascular diseases, etc.</td>
<td>[1-10]</td>
</tr>
<tr>
<td>Alginate-chitosan</td>
<td>PC12 cells, R208F cells, Human RBCs, HepG2 cells, BHK-21 cells, chondrocytes, and bone marrow stem cells</td>
<td>Liver failure treatment, myocardial therapy, bone tissue engineering, etc.</td>
<td>[18, 28-34]</td>
</tr>
<tr>
<td>Alginate-PLO*</td>
<td>Rat islets with Sertoli's cells</td>
<td>Diabetes</td>
<td>[137]</td>
</tr>
<tr>
<td>Alginate-PEG*</td>
<td>Islets</td>
<td>Diabetes</td>
<td>[138]</td>
</tr>
<tr>
<td>Alginate-gelatin</td>
<td>Feline renal fibroblast cells</td>
<td>Regenerative medicine and drug research</td>
<td>[102]</td>
</tr>
<tr>
<td>Alginate-gelatin-poly(vinyl alcohol)-acrylic terpolymer</td>
<td>Hepatocytes</td>
<td>Liver diseases</td>
<td>[139]</td>
</tr>
<tr>
<td>Agarose</td>
<td>Ifosfamide-activating cells</td>
<td>Cancer</td>
<td>[140]</td>
</tr>
<tr>
<td></td>
<td>Marrow stromal and embryonic stem cells</td>
<td>Regenerative medicine and tissue engineering</td>
<td>[116, 141]</td>
</tr>
<tr>
<td>Collagen</td>
<td>Mesenchymal stem cells</td>
<td>Bone tissue engineering</td>
<td>[86]</td>
</tr>
<tr>
<td>Hyaluronic acid</td>
<td>Embryonic stem cells</td>
<td>Regenerative medicine</td>
<td>[142]</td>
</tr>
<tr>
<td></td>
<td>Human dermal fibroblasts</td>
<td>Reduce scar formation and fibrotic disorders</td>
<td>[143]</td>
</tr>
<tr>
<td>Poly(vinyl alcohol)</td>
<td>Islets</td>
<td>Diabetes</td>
<td>[144, 145]</td>
</tr>
<tr>
<td>2-hydroxyethyl methacrylate</td>
<td>3T3 fibroblasts, CHO-K1</td>
<td>CNS diseases</td>
<td>[146]</td>
</tr>
<tr>
<td></td>
<td>Luciferase-modified CHO fibroblasts</td>
<td>Down regulate xenogenic immune response</td>
<td>[147]</td>
</tr>
<tr>
<td>Poly(lactic-co-glycolic acid)</td>
<td>P19 embryonic carcinoma cells</td>
<td>Nerve tissue engineering</td>
<td>[145]</td>
</tr>
</tbody>
</table>

* PLL (poly-L-lysine), PLO (poly-L-ornithine) and PEG (polyethylene glycol) for microcapsule coating and/or surface modification are not of natural origin.

#### 2.2. Methods for Cell Microencapsulation

A number of methods have been used to prepare cell-loaded microcapsules, including extrusion (electrostatic spray, air flow nozzle, and vibrating nozzle), emulsion/thermal gelation (agarose as core polymer), and microfluidic flow focusing approach [14, 39 - 46]. The two main factors that should be considered when choosing a microencapsulation method are the capability of maintaining high cell viability/function and controlling microcapsule size (including size distribution) and shape.
In emulsion methods, the aqueous phase (with living cells) is mixed and dispersed in an organic phase. When the dispersion reaches equilibrium, gel formation is initiated by cooling or by the addition of a gelling agent. Although the emulsion process could be easily scaled up, it has disadvantages including cell death caused by the significant shearing stress during emulsion and wide (Gaussian) size distribution [40]. In microfluidic methods based on flow focusing, miniaturized devices are used for better control of microcapsule characteristics. However, this method requires the use of organic solvents that makes it difficult to retrieve the microencapsulated cells [40, 47].

In extrusion methods, a cell/polymer mixture is extruded through a small tube or needle. The drops formed are allowed to fall freely into a gelation bath where the polymers are cross-linked to form hydrogel. The differences between the various extrusion methods are the driving force for extrusion and the method for liquid break up. Among them, the electrostatic spray method is promising because of the ease of operation, high efficiency, negligible damage to cells, and the possibility of preparing the microcapsules in a sterile environment [19, 40, 48].

In addition, there are non-traditional cell encapsulation techniques available. For example, cells have been encapsulated in hollow fiber for different in vivo transplantation needs and to improve the cell encapsulation efficiency and homogeneity of cell distribution within the biomatrix. Several hollow fiber systems have been developed for cell encapsulation with promising results, including poly(acrylonitrile-vinyl chloride) (PAN-PVC) hollow fiber membrane [49], gelatin-hydroxyphenylpropionic acid hydrogel fiber [50], and alginate hollow fiber [51].

2.3. Cells Studied for Microencapsulation

A variety of cells have been studied for cell microencapsulation in the following three categories:

Primary cells --- Primary cells are cells taken directly from a living organism, which is not immortalised, such as islets. Transplantation of encapsulated islets or islet cell aggregates, the first cell source used in microencapsulation for diabetes treatment, has been the most common application of cell encapsulation technology to date [3 - 5, 52 - 56]. Moreover, microencapsulation of human islets has been applied in clinical trials [57, 58]. Besides diabetes, primary cells have also been microencapsulated for treating neurodegenerative disorders (by transplantation of encapsulated choroid plexus), liver diseases (by transplantation of encapsulated hepatocytes), and neuropathic pain (by transplantation of encapsulated chromaffin cells) [59 - 64]. In addition, these studies have shown that microcapsules can serve as a 3D system to promote the survival and growth of the primary cells [63, 64].

Genetically engineered cells --- Genetically modified cells have been microencapsulated to serve as a living therapeutic delivery agent. This provides a promising way for the treatment of chronic diseases which require sustained release of therapeutic agents. However, considering most genetically engineered cells are from allogenetic or xenogeneic sources, immunoisolation is an important factor for the use of these cells. Research using these cells has been conducted for the treatment of diseases in the central nervous system, cardiovascular disorders, mucopolysaccharidosis type VII (MPSVII) disease, anemia, wound, bone fractures, and
A Phase I trial of ciliary neurotrophic factor (CNTF) delivered by intraocular implants of encapsulated cells has been completed by Sieving et al. [75]. The results show that delivery of CNTF using encapsulated cells is safe for the human retina even with severely compromised photoreceptors. Since a wide range of therapeutic agents can be produced by genetically engineered cells, this approach for delivering therapeutic products provides a potential therapy not only for retinal neurodegeneration but many other diseases.

**Stem cells** —— Microencapsulation of stem cells as a therapeutic strategy for regenerative medicine, tissue engineering and gene therapy (stem cell as gene carrier) is an area of increasing interest [3, 76 - 80]. Moreover, microcapsule can be adopted as a 3D microenvironment to study the proliferation and desired differentiation of embryonic stem cells and bone marrow (BM)-derived mesenchymal stem cells (MSCs) cells [81, 82]. Maintenance of their undifferentiated characteristics and induction of specific differentiation of stem cells has been investigated [83 - 91]. Work by Maguire et al. [84] on embryonic stem (ES) cell encapsulation using alginate-PLL polymers showed high cell viability even post-decapsulation *in vitro* (> 90 %). Evaluation of the hepatocyte-specific functions such as albumin synthesis and urea secretion revealed that the encapsulated cells adopted hepatogenic differentiation. Cardiac cells could also be generated from encapsulated ES cells in alginate-PLL microcapsules [92]. Both mouse and human MSCs have been differentiated into osteogenic lineages in microcapsules [86, 93]. Moreover, MSCs can act as feeder cells. Co-encapsulation of MSC and hepatocytes was found to enhance the viability and function of hepatocytes *in vitro* and *in vivo* [61, 77, 94, 95]. Studies have also been conducted on osteogenic differentiation of ES cells in alginate hydrogel and formation of embryoid body-like spherical tissues in hollow-core agarose microcapsules [96, 97]. Microcapsules can be used to encapsulate human ES cells into definitive endoderm for myocardial cell therapy [81, 98, 99]. Encapsulated stem cells could also be used as a tool for stem-cell mediated cardiomyoplasty [76]. Moreover, previous research has shown that both the intrinsic characteristics of stem cells and their microenvironment regulate the fate of stem cells [76, 96, 100, 101]. In particular, the cells may produce auto-regulatory proteins during differentiation/maturation. Microcapsules may either induce or conserve this resource by retaining them within the capsules (autocrine effects). Many paracrine responses may direct differentiation/maturation (e.g., spontaneous ES differentiation into hepatocytes via embryoid body culture) [76, 96, 100, 101]. Therefore, the main objective of stem cell microencapsulation technology is to maintain the undifferentiated state of the cells and for controlled differentiation with the desired functions of the differentiated cells.

3. **ENCAPSULATION OF MAMMALIAN CELLS IN SMALL (≤ ~ 100 µm) MICROCAPSULES**

Several recent studies highlight the importance of reducing the microcapsule size for cell-based medicine [11, 19, 102]. Small microcapsules offer many advantages in transplantation, considering that clinical practice of microencapsulation technology has been limited by the sites of transplantation and inadequate transport of nutrients to encapsulated cells [5, 7, 102]. For a sphere, the specific surface area (the surface area
per unit volume) increases as the diameter decreases. Therefore, decrease in microcapsule diameter should reduce resistance to the transport of oxygen and nutrients to the encapsulated cells and enhance transfer of therapeutic products produced by the cells out of the microcapsule [5, 7, 102 - 104]. Moreover, small microcapsules have been shown to have better mechanical properties and stability that lead to better biocompatibility (presumably by minimizing the chance of microcapsule burst) [43, 102, 104, 105]. For example, agarose microcapsules ≤ 100 µm in diameter were shown to be more biocompatible than that of 300-1000 µm [102, 106, 107]. Remarkably, it has been reported that reduction in capsule size mitigates foreign body response to implanted microcapsules in host [108], reduces surgical trauma and allows more choices of implantation sites, especially immune-privileged sites such as the spleen [7, 102, 103]. Moreover, it has been reported that cryopreservation of microencapsulated cells is challenging when the size of the microcapsules exceeds 200 µm (more details in section 4) [109]. Using small cell-loaded microcapsules could improve the cell viability post cryopreservation, particularly by ultrafast vitrification [110-112].

Successful preparation of small cell-loaded alginate microcapsules from 100 to 200 µm (in diameter) has been reported in several recent studies using microfluidic channel/nozzle devices [7, 43, 103, 105, 113-116]. However, cell-loaded microcapsules prepared using the electrostatic spray method reported in the literature are usually greater than 200 µm. Considering the advantages of electrostatic spray method as discussed in the previous section, we have successfully applied it to encapsulate mammalian cells in small (~ 100 µm) alginate microcapsules with good morphology and high cell viability (> 95%) by optimizing the manufacturing parameters [117].

4. CRYOPRESERVATION OF MICROENCAPSULATED CELLS

Successful cryopreservation of microencapsulated cells can promote their availability as cell-based medicine, by establishing banks of living cells for wide distribution to end users whenever needed. Cryopreservation of microencapsulated cells has been investigated through both slow freezing (i.e., phase change of water from liquid to ice crystals) and vitrification (i.e., the transformation of liquid water into an amorphous, solid like material instead of ice crystals) over the past 15 years [118 - 120]. Efforts have been made to optimize the cryopreservation protocol for maintaining cell viability and function as well as the integrity of the microcapsules [118 - 120]. However, the fundamental biophysics of the microencapsulated cells in response to temperature and osmotic excursion (due to cryoprotective agents (CPA) addition and freezing induced dehydration) during cryopreservation has not been well studied.

4.1. Cryopreservation of Microencapsulated Cells by Slow-Freezing

The slow-freezing method has been employed to cryopreserve a number of microencapsulated cells as detailed below.

**Hepatocytes** — Canaple et al. [121] encapsulated Murine hepatocytes in specially designed multicomponent capsules formed by polyelectrolyte complexation of sodium alginate, cellulose sulphate and poly(methylene-co-guanidine) hydrochloride. Encapsulated hepatocytes retained their specific functions for a long period after
cryopreservation by slow freezing involving the following procedures: microencapsulated hepatocytes with CPA (10% dimethyl sulfoxide (DMSO)) in cryovials were stored at 4°C for 30 min, -20°C for 2 h, -80°C for 24 h, and then stored in liquid nitrogen (-196°C). However, the freezing process was not well controlled (ice formation in aqueous solution is a stochastic event when cooled at -20°C) which may lead to inconsistent results. Moreover, the cell viability was not high (15% of cell viability loss) and broken microcapsules were observed after cryopreservation [121]. Haque et al. [32] investigated the ability of Alginate-Chitosan (AC) microcapsules to support hepatocyte proliferation and function, and showed improved performance compared with the widely studied APA membrane in terms of both immunogenicity and cryopreservation properties. However, the structural differences of APA (hollow core) and AC (solid core) microcapsules were not considered.

Islets —— Different kinds of islets have been successfully cryopreserved after microencapsulation. Two slow-cooling protocols were compared in Zhou’s study [122]: (1) seeding extracellular ice at -7.5°C, cooling to -45°C at 0.2°C/min, and then plunging in liquid nitrogen, and (2) cooling from 4 to -70°C at 1°C/min directly without ice seeding (note: ice seeding means seeding extracellular ice at a high sub-zero temperature usually > -10°C). The two procedures yielded significantly different results when applied to porcine islets. It was noted that a closely controlled cooling rate is necessary in dealing with the delicate and sensitive porcine islets. In addition, ice seeding played a significant role in retaining the physiological competence of the cryopreserved islets. These factors make the cryopreservation protocol complicated and time-dependent, restricting its further applications. Two slow-freezing protocols (with ice-seeding), with a difference only in cooling rate (0.3 versus 5°C/min), were compared in Li’s study [48]. Only slight differences were observed. The possible reason is that the two cooling rates were both slow enough to dehydrate the cells, and/or the ice seeding step was more important than cooling rate in determining the cell viability and function post cryopreservation by slow freezing. Stiegler et al. [123] investigated cryopreservation of insulin-producing cells (HIT-T15) in sodium cellulose sulfate. The results showed that the cryoprotective capability of glycerol was similar to DMSO for non-encapsulated cells but better than DMSO for microencapsulated cells. The effect of microencapsulation on the morphology and endocrine function of cryopreserved neonatal porcine islet-like cell clusters (ICCs) was also studied [124]. The results suggested that microencapsulation is useful for cryopreserved ICCs to effectively maintain their fine morphology and to recover their endocrine function. Woods et al. [125] investigated the effect of two cryoprotectants (DMSO and ethylene glycol) on the volume change of Ca2+ alginate microcapsules, and the effects of microencapsulation on the volumetric response of human and canine pancreatic islets during cryoprotectant equilibration. The results demonstrate that there are cryoprotectant and alginate-specific interactions, and that microencapsulation modulates the degree of osmotically induced shrinkage of islets. The development or modification of existing cryopreservation protocols to improve post-cryopreservation recovery or function should take these factors into account.

Other Cells —— Cryopreservation of microencapsulated kidney, PC 12 and transgenic cells has also been investigated [118, 119, 126]. For example, Heng et al.
used a slow-freezing protocol (cooling at 3~4°C/min from room temperature to -80°C) for the cryopreservation of microencapsulated kidney cells. A high concentration of cryoprotectant (2.8 M DMSO and 0.25 M sucrose) was reported to be required for maintaining high cell viability post cryopreservation. Nevertheless, microcapsule integrity was still compromised (~ 60% intact) at this high cryoprotectant concentration. Murua et al. [127] investigated the long-term storage of microencapsulated myoblasts by cryopreservation. A total of 10% DMSO was used as the cryoprotectant for a slow-freezing procedure (1 h cooling at -20°C, and 23 h cooling at -80°C, followed by cooling in liquid nitrogen). However, a 42% reduction in Epo release from the encapsulated cells after cryopreservation was noted, which may be a result of the use of a sub-optimal cryopreservation protocol (i.e., without ice-seeding) and the relative large microcapsule (> 400 µm) for encapsulating the cells. More recently, cryopreservation of microencapsulated neurospheres was also studied with promising outcome [128]. Moreover, application of cryopreserved transgenic mesenchymal stem-cell-loaded capsules (500-600 µm) in intracerebral hemorrhage treatment has entered the stage of clinical trial [129].

4.2. Cryopreservation of Microencapsulated Cells by Vitrification
Although slow-freezing can provide utilitarian (but sub-optimal) outcome for banking microencapsulated cells, cell injury due to ice formation either inside or outside the cells is inevitable. Significant intracellular ice formation is lethal to the cells and extracellular ice formation may induce significant cell dehydration that can cause physicochemical injury to the encapsulated cells. Moreover, the loss of integrity of the relatively large (~ 250 µm) microcapsule was observed during slow-freezing, which may mechanically damage the encapsulated cells [118]. An alternative approach for cryopreservation is vitrification, transformation of liquid water into a solid-like, glassy substance with negligible ice formation (i.e., glass transition or cooling without freezing) [130, 131]. A few studies have reported cryopreservation of microencapsulated cells through vitrification with an unusually high (up to 7 M) concentration of cryoprotectants [132, 133]. Although the results show that vitrification is superior to slow-freezing in maintaining both the cell viability/function and the microcapsule integrity, the potential osmotic and metabolic damage to the encapsulated cells by the usually high concentration of cryoprotectants is still a significant concern. Recently, we reported morphological and biophysical observations, using cryomicroscopy and scanning calorimetry, of small (~ 100 µm) alginate microcapsules after cryopreservation [134]. It was found that water enclosed in the microcapsules could be preferentially vitrified at a low concentration of cryoprotectants (10% DMSO) when cooled at 100°C/min. As a result, microencapsulation of living cells in a small alginate microcapsule significantly augments cell survival (~ 90% for encapsulated cells versus ~ 42% for non encapsulated cells, Figure 2) after cryopreservation with 10% DMSO and cooling the cells contained in 400 µm quartz microcapillaries in liquid nitrogen. Therefore, the small alginate microcapsule is good for not only encapsulating stress-sensitive (to ice formation and high concentration of cryoprotectants) living cells but protecting the cells from cryoinjury during cryopreservation [134].
Figure 2. Phase contrast (A and C) and fluorescence micrographs (B and D) of non-encapsulated (A and B) and encapsulated (C and D) cells after cryopreservation by vitrification. In the fluorescence micrographs (B and D), live and dead cells were stained green and red, respectively. The cell viability were high (> 95%) for both encapsulated and non-encapsulated cells before cryopreservation. Scale bars: 100 µm. Figure reprinted and redrawn from reference [134] with permission from Springer Publishing Co.

5. CHALLENGES OF CELL MICROENCAPSULATION FOR CLINICAL APPLICATIONS
Although the technology of cell microencapsulation has been greatly improved with promising outcomes even in clinical trials and clinical practices [57, 58, 71, 75], there are still several limitations that need to be overcome. Firstly, the systemic biocompatibility of encapsulated cells needs to be enhanced. The fibrotic overgrowth (see Figure 3) may occur due to serious host immune response that can result in cell death (transplantation failure) through complicated mechanisms including the production of excessive free radicals. Moreover, necrosis may occur due to the use of improper encapsulation materials and/or an insufficient supply of nutrition. Dying cells may compromise the healthy neighboring cells and elicit antigenic responses in the long run [135]. Therefore, a high in vivo survival rate of encapsulated cells has to be achieved to ensure successful transplantation. This requires that the biomaterials used
are systemically biocompatible and the microcapsule is capable of functioning as a semi-permeable membrane with proper porosity to protect the encapsulated cells from host immune attack while ensuring adequate supply of nutrients and discharge of metabolic wastes. Secondly, capsule breakage (see Figure 3) after transplantation may occur if the mechanical strength and stability of the microcapsules is poor. Cell leakage may lead to serious immune responses and other unexpected consequences. Thirdly, it may be difficult to develop one type of microcapsule system for all kinds of cells. For example, microcapsules made of non-biodegradable materials may not be suitable for applications that need tissue integration of the encapsulated cells. Lastly, regulatory considerations of the encapsulated cells in clinical practice need to be taken into account [136]. Therefore, a standard for comprehensive characterization of surface properties, permeability, mechanical strength, and other properties has to be established to ensure systemic biocompatibility and stability of the microcapsules [38].

Figure 3.  Fibrosis around encapsulated cells and broken microcapsules 2 days after transplantation, due to poor systemic biocompatibility and low mechanical stability/strength of microcapsules to encapsulate living cells. Figure reprinted and redrawn from reference [138] with permission from Elsevier.
6. SUMMARY AND OUTLOOK

Cell microencapsulation is a promising technology to advance the emerging living-cell-based medicine. However, it is important to further improve the in vivo biocompatibility of the microcapsule systems by identifying systemically biocompatible materials to synthesize microcapsules and by reducing the size of the microcapsules. Further, the microcapsules should be designed with desired mechanical strength for stability and the desired porosity for adequate biotransport of nutrients and metabolic wastes. In addition, microcapsules with an appropriate extracellular matrix (e.g., collagen) in their core and co-encapsulation of multiple types of cells (e.g., both stromal and parenchymal) for better cell attachment and survival/function could be another important future direction. Banking the microencapsulated cells has been achieved mainly by cryopreservation via slow-freezing. On the other hand, vitrification of the microencapsulated cells is becoming increasingly popular as it can retain not only a high cell viability/function but also intact microcapsule morphology, particularly when vitrification is achieved with a low, nontoxic concentration (≤ ~1.5 M) of cryoprotectants. For clinical implementation of cell-based medicine, it is desirable to bank the living cell-based products at the ambient temperature, an area that deserves further research. The biophysical responses of encapsulated cells to cooling/freezing and drying should be investigated for the development of optimal cryo and dry (lyo) preservation protocols.

ACKNOWLEDGEMENTS

This work was partially supported by grants from the National Science Foundation (CBET-1154965) and National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health (R01EB012108). We thank Kyle Gilstrap for proofreading this manuscript.

CONFLICT OF INTEREST: None.

REFERENCES


